Drug Monograph

Drug/Drug Class: **Lanoxin™ (digoxin) tablet / cardiac glycoside**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Lanoxin™ is available in a new 187.5 mcg, unscored tablet containing 187.5 mg of digoxin.
Manufacturer:	DSM Pharmaceuticals, Inc. Greenville, NC 27834
Indications:	Lanoxin™ is approved for the treatment of mild to moderate heart failure and to control the resting ventricular rate in chronic atrial fibrillation in adults as well as increasing myocardial contractility in pediatric patient with heart failure.
Costs:	$2.40 per tablet of Lanoxin™ WholesaleAcquisitionCost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ No PA Required

Prepared By: Katie Wilbers, PharmD
Date: May 12, 2014